A P-gp vesicular transport inhibition assay - Optimization and validation for drug-drug interaction testing

European Journal of Pharmaceutical Sciences

Volumn 49, Issue 4, 2013, Pages 773-781

  Herédi Szabó, Krisztina ^a   Palm, Johan E ^b   Andersson, Tommy B ^b   Pál, Ákos ^a   Méhn, Dóra ^a   Fekete, Zsolt ^a   Beéry, Erzsébet ^a   Jakab, Katalin Tauberné ^a   Jani, Márton ^a   Krajcsi, Peter ^a  

^a SOLVO BIOTECHNOLOGY   (Hungary)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

ABCB1; DDI; Human cell membrane; N methyl quinidine; P glycoprotein; Vesicular uptake

Indexed keywords

DIGOXIN; MULTIDRUG RESISTANCE PROTEIN; N METHYL QUINIDINE; PACLITAXEL; QUINIDINE; UNCLASSIFIED DRUG; VESICULAR TRANSPORT PROTEIN; VINBLASTINE;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG DETERMINATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MEMBRANE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; VALIDATION PROCESS; WESTERN BLOTTING;

EID: 84880182694     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2013.04.032     Document Type: Article

References (89)

1. Acharya, P., O'Connor, M.P., Polli, J.W., Ayrton, A., Ellens, H., Bentz, J., 2008. Kinetic identification of membrane transporters that assist P-glycoprotein-mediated transport of digoxin and loperamide through a confluent monolayer of MDCKIIhMDR1 cells. Drug Metab. Dispos. 36, 452-460. (Pubitemid 351185760)
2. Aller, S.G., Yu, J., Ward, A., Weng, Y., Chittaboina, S., Zhuo, R., Harrell, P.M., Trinh, Y.T., Zhang, Q., Urbatsch, I.L., Chang, G., 2009. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 323, 1718-1722.
3. Altmann, F., Staudacher, E., Wilson, I.B., Marz, L., 1999. Insect cells as hosts for the expression of recombinant glycoproteins. Glycoconj. J. 16, 109-123. (Pubitemid 29472137)
4. Amsden, G.W., Nafziger, A.N., Foulds, G., Cabelus, L.J., 2000. A study of the pharmacokinetics of azithromycin and nelfinavir when coadministered in healthy volunteers. J. Clin. Pharmacol. 40, 1522-1527.
5. Angelin, B., Arvidsson, A., Dahlqvist, R., Hedman, A., Schenck-Gustafsson, K., 1987. Quinidine reduces biliary clearance of digoxin in man. Eur. J. Clin. Invest. 17, 262-265. (Pubitemid 17083009)
6. Balimane, P.V., Marino, A., Chong, S., 2008. P-gp inhibition potential in cell-based models: which "calculation" method is the most accurate? AAPS J. 10, 577-586.
7. Bartholome, K., Rius, M., Letschert, K., Keller, D., Timmer, J., Keppler, D., 2007. Databased mathematical modeling of vectorial transport across double-transfected polarized cells. Drug Metab. Dispos. 35, 1476-1481. (Pubitemid 47296038)
8. Bermejo, M., Avdeef, A., Ruiz, A., Nalda, R., Ruell, J.A., Tsinman, O., Gonzalez, I., Fernandez, C., Sanchez, G., Garrigues, T.M., Merino, V., 2004. PAMPA - a drug absorption in vitro model 7. Comparing rat in situ, Caco-2, and PAMPA permeability of fluoroquinolones. Eur. J. Pharm. Sci. 21, 429-441. (Pubitemid 38283916)
9. Callies, S., de Alwis, D.P., Harris, A., Vasey, P., Beijnen, J.H., Schellens, J.H., Burgess, M., Aarons, L., 2003. A population pharmacokinetic model for paclitaxel in the presence of a novel P-gp modulator, Zosuquidar Trihydrochloride (LY335979). Br. J. Clin. Pharmacol. 56, 46-56. (Pubitemid 36886488)
10. Chin, K.V., Tanaka, S., Darlington, G., Pastan, I., Gottesman, M.M., 1990. Heat shock and arsenite increase expression of the multidrug resistance (MDR1) gene in human renal carcinoma cells. J. Biol. Chem. 265, 221-226.
11. Damle, B.D., Mummaneni, V., Kaul, S., Knupp, C., 2002. Lack of effect of simultaneously administered didanosine encapsulated enteric bead formulation (Videx EC) on oral absorption of indinavir, ketoconazole, or ciprofloxacin. Antimicrob. Agents Chemother. 46, 385-391. (Pubitemid 34087184)
12. Danner, S.A., Carr, A., Leonard, J.M., Lehman, L.M., Gudiol, F., Gonzales, J., Raventos, A., Rubio, R., Bouza, E., Pintado, V., et al., 1995. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N. Engl. J. Med. 333, 1528-1533.
13. Ding, R., Tayrouz, Y., Riedel, K.D., Burhenne, J., Weiss, J., Mikus, G., Haefeli, W.E., 2004. Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers. Clin. Pharmacol. Ther. 76, 73-84. (Pubitemid 38844736)
14. Dolghih, E., Bryant, C., Renslo, A.R., Jacobson, M.P., 2011. Predicting binding to pglycoprotein by flexible receptor docking. PLoS Comput. Biol. 7, e1002083.
15. European Medicines Agency-Guidance, 2010. .
16. European Medicines Agency-Guidance, 2012. .
17. Faria, A., Monteiro, R., Pestana, D., Martel, F., de Freitas, V., Mateus, N., Calhau, C., 2010. Impact of culture media glucose levels on the intestinal uptake of organic cations. Cytotechnology 62, 23-29.
18. Food and Drug Administration-Guidance, 2006. .
19. Food and Drug Administration-Guidance, 2012. .
20. Fenner, K.S., Troutman, M.D., Kempshall, S., Cook, J.A., Ware, J.A., Smith, D.A., Lee, C.A., 2009. Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug. Clin. Pharmacol. Ther. 85, 173-181.
21. Giaccone, G., Linn, S.C., Welink, J., Catimel, G., Stieltjes, H., van der Vijgh, W.J., Eeltink, C., Vermorken, J.B., Pinedo, H.M., 1997. A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors. Clin. Cancer Res. 3, 2005-2015. (Pubitemid 27505127)
22. Giacomini, K.M., Huang, S.M., Tweedie, D.J., Benet, L.Z., Brouwer, K.L., Chu, X., Dahlin, A., Evers, R., Fischer, V., Hillgren, K.M., Hoffmaster, K.A., Ishikawa, T., Keppler, D., Kim, R.B., Lee, C.A., Niemi, M., Polli, J.W., Sugiyama, Y., Swaan, P.W., Ware, J.A., Wright, S.H., Yee, S.W., Zamek-Gliszczynski, M.J., Zhang, L., 2010. Membrane transporters in drug development. Nat. Rev. Drug Discov. 9, 215-236.
23. Glavinas, H., Mehn, D., Jani, M., Oosterhuis, B., Heredi-Szabo, K., Krajcsi, P., 2008. Utilization of membrane vesicle preparations to study drug-ABC transporter interactions. Expert Opin. Drug Metab. Toxicol. 4, 721-732. (Pubitemid 352003195)
24. Glavinas, H., von Richter, O., Vojnits, K., Mehn, D., Wilhelm, I., Nagy, T., Janossy, J., Krizbai, I., Couraud, P., Krajcsi, P., 2011. Calcein assay: a high-throughput method to assess P-gp inhibition. Xenobiotica 41, 712-719.
25. Grub, S., Bryson, H., Goggin, T., Ludin, E., Jorga, K., 2001. The interaction of saquinavir (soft gelatin capsule) with ketoconazole, erythromycin and rifampicin: comparison of the effect in healthy volunteers and in HIV-infected patients. Eur. J. Clin. Pharmacol. 57, 115-121. (Pubitemid 32449131)
26. Hayeshi, R., Hilgendorf, C., Artursson, P., Augustijns, P., Brodin, B., Dehertogh, P., Fisher, K., Fossati, L., Hovenkamp, E., Korjamo, T., Masungi, C., Maubon, N., Mols, R., Mullertz, A., Monkkonen, J., O'Driscoll, C., Oppers-Tiemissen, H.M., Ragnarsson, E.G., Rooseboom, M., Ungell, A.L., 2008a. Comparison of drug transporter gene expression and functionality in Caco-2 cells from 10 different laboratories. Eur. J. Pharm. Sci. 35, 383-396.
27. Hayeshi, R., Masimirembwa, C., Mukanganyama, S., Ungell, A.L., 2008b. Lysosomal trapping of amodiaquine: impact on transport across intestinal epithelia models. Biopharm. Drug Dispos. 29, 324-334.
28. Heikkinen, A.T., Korjamo, T., Lepikko, V., Monkkonen, J., 2010. Effects of experimental setup on the apparent concentration dependency of active efflux transport in in vitro cell permeation experiments. Mol. Pharm. 7, 605-617.
29. Hemauer, S.J., Patrikeeva, S.L., Nanovskaya, T.N., Hankins, G.D., Ahmed, M.S., 2009. Opiates inhibit paclitaxel uptake by P-glycoprotein in preparations of human placental inside-out vesicles. Biochem. Pharmacol. 78, 1272-1278.
30. Hidalgo, I.J., Raub, T.J., Borchardt, R.T., 1989. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology 96, 736-749. (Pubitemid 19057595)
31. Homolya, L., Hollo, M., Muller, M., Mechetner, E.B., Sarkadi, B., 1996. A new method for a quantitative assessment of P-glycoprotein-related multidrug resistance in tumour cells. Br. J. Cancer 73, 849-855. (Pubitemid 26111312)
32. Hooiveld, G.J., Heegsma, J., van Montfoort, J.E., Jansen, P.L., Meijer, D.K., Muller, M., 2002. Stereoselective transport of hydrophilic quaternary drugs by human MDR1 and rat Mdr1b P-glycoproteins. Br. J. Pharmacol. 135, 1685-1694. (Pubitemid 36132702)
33. Horie, K., Tang, F., Borchardt, R.T., 2003. Isolation and characterization of Caco-2 subclones expressing high levels of multidrug resistance protein efflux transporter. Pharm. Res. 20, 161-168. (Pubitemid 36269722)
34. Kalvass, J.C., Pollack, G.M., 2007. Kinetic considerations for the quantitative assessment of efflux activity and inhibition: implications for understanding and predicting the effects of efflux inhibition. Pharm. Res. 24, 265-276. (Pubitemid 46072186)
35. Kirby, B.J., Collier, A.C., Kharasch, E.D., Whittington, D., Thummel, K.E., Unadkat, J.D., 2012. Complex drug interactions of the HIV protease inhibitors 3: effect of simultaneous or staggered dosing of digoxin and ritonavir, nelfinavir, rifampin, or bupropion. Drug Metab. Dispos. 40, 610-616.
36. Kis, E., Ioja, E., Nagy, T., Szente, L., Heredi-Szabo, K., Krajcsi, P., 2009a. Effect of membrane cholesterol on BSEP/Bsep activity: species specificity studies for substrates and inhibitors. Drug Metab. Dispos. 37, 1878-1886.
37. Kis, E., Rajnai, Z., Ioja, E., Heredi Szabo, K., Nagy, T., Mehn, D., Krajcsi, P., 2009b. Mouse Bsep ATPase assay: a nonradioactive tool for assessment of the cholestatic potential of drugs. J. Biomol. Screen. 14, 10-15.
38. Korjamo, T., Kemilainen, H., Heikkinen, A.T., Monkkonen, J., 2007. Decrease in intracellular concentration causes the shift in Km value of efflux pump substrates. Drug Metab. Dispos. 35, 1574-1579. (Pubitemid 47296050)
39. Kovarik, J.M., Rigaudy, L., Guerret, M., Gerbeau, C., Rost, K.L., 1999. Longitudinal assessment of a P-glycoprotein-mediated drug interaction of valspodar on digoxin. Clin. Pharmacol. Ther. 66, 391-400. (Pubitemid 29494132)
40. Leizorovicz, A., Piolat, C., Boissel, J.P., Sanchini, B., Ferry, S., 1984. Comparison of two long-acting forms of quinidine. Br. J. Clin. Pharmacol. 17, 729-734. (Pubitemid 14068507)
41. Litman, T., Skovsgaard, T., Stein, W.D., 2003. Pumping of drugs by P-glycoprotein: a two-step process? J. Pharmacol. Exp. Ther. 307, 846-853. (Pubitemid 37494200)
42. Loo, T.W., Bartlett, M.C., Clarke, D.M., 2003. Substrate-induced conformational changes in the transmembrane segments of human P-glycoprotein. Direct evidence for the substrate-induced fit mechanism for drug binding. J. Biol. Chem. 278, 13603-13606. (Pubitemid 36799891)
43. Lumen, A.A., Acharya, P., Polli, J.W., Ayrton, A., Ellens, H., Bentz, J., 2010. If the KI is defined by the free energy of binding to P-glycoprotein, which kinetic parameters define the IC50 for the Madin-Darby canine kidney II cell line overexpressing human multidrug resistance 1 confluent cell monolayer? Drug Metab. Dispos. 38, 260-269.
44. Madaras-Kelly, K.J., Daniels, C., Hegbloom, M., Thompson, M., 2002. Pharmacodynamic characterization of efflux and topoisomerase IV-mediated fluoroquinolone resistance in Streptococcus pneumoniae. J. Antimicrob. Chemother. 50, 211-218. (Pubitemid 34918850)
45. Malingre, M.M., Beijnen, J.H., Rosing, H., Koopman, F.J., Jewell, R.C., Paul, E.M., Ten Bokkel Huinink, W.W., Schellens, J.H., 2001. Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients. Br. J. Cancer 84, 42-47. (Pubitemid 32102502)
46. Margolis, J.M., Obach, R.S., 2003. Impact of nonspecific binding to microsomes and phospholipid on the inhibition of cytochrome P4502D6: implications for relating in vitro inhibition data to in vivo drug interactions. Drug Metab. Dispos. 31, 606-611. (Pubitemid 36444170)
47. Martin, C., Berridge, G., Higgins, C.F., Mistry, P., Charlton, P., Callaghan, R., 2000. Communication between multiple drug binding sites on P-glycoprotein. Mol. Pharmacol. 58, 624-632.
48. Matsushima, S., Maeda, K., Kondo, C., Hirano, M., Sasaki, M., Suzuki, H., Sugiyama, Y., 2005. Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J. Pharmacol. Exp. Ther. 314, 1059-1067. (Pubitemid 41205969)
49. Meerum Terwogt, J.M., Malingre, M.M., Beijnen, J.H., ten Bokkel Huinink, W.W., Rosing, H., Koopman, F.J., van Tellingen, O., Swart, M., Schellens, J.H., 1999. Coadministration of oral cyclosporin A enables oral therapy with paclitaxel. Clin. Cancer Res. 5, 3379-3384.
50. Meredith, P.A., Elliott, H.L., Pasanisi, F., Kelman, A.W., Sumner, D.J., Reid, J.L., 1985. Verapamil pharmacokinetics and apparent hepatic and renal blood flow. Br. J. Clin. Pharmacol. 20, 101-106. (Pubitemid 15240600)
51. Merry, C., Barry, M.G., Mulcahy, F., Halifax, K.L., Back, D.J., 1997. Saquinavir pharmacokinetics alone and in combination with nelfinavir in HIV-infected patients. AIDS 11, F117-120. (Pubitemid 27500953)
52. Merry, C., Barry, M.G., Mulcahy, F., Ryan, M., Tjia, J.F., Halifax, K.L., Breckenridge, A.M., Back, D.J., 1998. The pharmacokinetics of combination therapy with nelfinavir plus nevirapine. Aids 12, 1163-1167. (Pubitemid 28302418)
53. Morschhauser, F., Zinzani, P.L., Burgess, M., Sloots, L., Bouafia, F., Dumontet, C., 2007. Phase I/II trial of a P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin's lymphoma. Leuk. Lymphoma 48, 708-715. (Pubitemid 46605542)
54. Muller, M., Mayer, R., Hero, U., Keppler, D., 1994. ATP-dependent transport of amphiphilic cations across the hepatocyte canalicular membrane mediated by mdr1 P-glycoprotein. FEBS Lett. 343, 168-172. (Pubitemid 24126669)
55. Nies, A.T., Herrmann, E., Brom, M., Keppler, D., 2008. Vectorial transport of the plant alkaloid berberine by double-transfected cells expressing the human organic cation transporter 1 (OCT1, SLC22A1) and the efflux pump MDR1 Pglycoprotein (ABCB1). Naunyn Schmiedebergs Arch. Pharmacol. 376, 449-461.
56. Noe, J., Stieger, B., Meier, P.J., 2002. Functional expression of the canalicular bile salt export pump of human liver. Gastroenterology 123, 1659-1666. (Pubitemid 35231665)
57. Pal, A., Mehn, D., Molnar, E., Gedey, S., Meszaros, P., Nagy, T., Glavinas, H., Janaky, T., von Richter, O., Bathori, G., Szente, L., Krajcsi, P., 2007. Cholesterol potentiates ABCG2 activity in a heterologous expression system: improved in vitro model to study function of human ABCG2. J. Pharmacol. Exp. Ther. 321, 1085-1094. (Pubitemid 46762703)
58. Paulusma, C.C., de Waart, D.R., Kunne, C., Mok, K.S., Elferink, R.P., 2009. Activity of the bile salt export pump (ABCB11) is critically dependent on canalicular membrane cholesterol content. J. Biol. Chem. 284, 9947-9954.
59. Pedersen, J.M., Matsson, P., Bergstrom, C.A., Norinder, U., Hoogstraate, J., Artursson, P., 2008. Prediction and identification of drug interactions with the human ATPbinding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2). J. Med. Chem. 51, 3275-3287. (Pubitemid 351821886)
60. Planting, A.S., Sonneveld, P., van der Gaast, A., Sparreboom, A., van der Burg, M.E., Luyten, G.P., de Leeuw, K., de Boer-Dennert, M., Wissel, P.S., Jewell, R.C., Paul, E.M., Purvis Jr., N.B., Verweij, J., 2005. A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 55, 91-99. (Pubitemid 40064500)
61. Polli, J.W., Wring, S.A., Humphreys, J.E., Huang, L., Morgan, J.B., Webster, L.O., Serabjit-Singh, C.S., 2001. Rational use of in vitro P-glycoprotein assays in drug discovery. J. Pharmacol. Exp. Ther. 299, 620-628. (Pubitemid 32979675)
62. Rautio, J., Humphreys, J.E., Webster, L.O., Balakrishnan, A., Keogh, J.P., Kunta, J.R., Serabjit-Singh, C.J., Polli, J.W., 2006. In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates. Drug Metab. Dispos. 34, 786-792.
63. Robson, S., Neuberger, J., Keller, H.P., Abisch, E., Neiderberger, W., von Graffenried, B., Williams, R., 1984. Pharmacokinetic study of cyclosporin A (Sandimmun) in patients with primary biliary cirrhosis. Br. J. Clin. Pharmacol. 18, 627-631. (Pubitemid 14009962)
64. Rodin, S.M., Johnson, B.F., Wilson, J., Ritchie, P., Johnson, J., 1988. Comparative effects of verapamil and isradipine on steady-state digoxin kinetics. Clin. Pharmacol. Ther. 43, 668-672.
65. Schlemmer, S.R., Sirotnak, F.M., 1994. Functional studies of P-glycoprotein in insideout plasma membrane vesicles derived from murine erythroleukemia cells overexpressing MDR 3. Properties and kinetics of the interaction of vinblastine with P-glycoprotein and evidence for its active mediated transport. J. Biol. Chem. 269, 31059-31066.
66. Schmitt, C., Kaeser, B., Riek, M., Bech, N., Kreuzer, C., 2010. Effect of saquinavir/ritonavir on P-glycoprotein activity in healthy volunteers using digoxin as a probe. Int. J. Clin. Pharmacol. Ther. 48, 192-199.
67. Shaffer, C.L., Scialis, R.J., Rong, H., Obach, R.S., 2012. Using Simcyp to project human oral pharmacokinetic variability in early drug research to mitigate mechanismbased adverse events. Biopharm. Drug Dispos. 33, 72-84.
68. Shirasaka, Y., Sakane, T., Yamashita, S., 2008. Effect of P-glycoprotein expression levels on the concentration-dependent permeability of drugs to the cell membrane. J. Pharm. Sci. 97, 553-565.
69. Simpson, K., Jarvis, B., 2000. Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria. Drugs 59, 301-321. (Pubitemid 30168518)
70. Smith, P.K., Krohn, R.I., Hermanson, G.T., Mallia, A.K., Gartner, F.H., Provenzano, M.D., Fujimoto, E.K., Goeke, N.M., Olson, B.J., Klenk, D.C., 1985. Measurement of protein using bicinchoninic acid. Anal. Biochem. 150, 76-85. (Pubitemid 16258399)
71. Sugano, K., Shirasaka, Y., Yamashita, S., 2011. Estimation of Michaelis-Menten constant of efflux transporter considering asymmetric permeability. Int. J. Pharm. 418, 161-167.
72. Sun, H., Chow, E.C., Liu, S., Du, Y., Pang, K.S., 2008. The Caco-2 cell monolayer: usefulness and limitations. Expert Opin. Drug Metab. Toxicol. 4, 395-411. (Pubitemid 351728514)
73. Tachibana, T., Kitamura, S., Kato, M., Mitsui, T., Shirasaka, Y., Yamashita, S., Sugiyama, Y., 2010. Model analysis of the concentration-dependent permeability of P-gp substrates. Pharm. Res. 27, 442-446.
74. Takara, K., Tsujimoto, M., Ohnishi, N., Yokoyama, T., 2002. Digoxin up-regulates MDR1 in human colon carcinoma Caco-2 cells. Biochem. Biophys. Res. Commun. 292, 190-194. (Pubitemid 34687347)
75. Tang, W., Stearns, R.A., Miller, R.R., Ngui, J.S., Mathvink, R.J., Weber, A.E., Kwei, G.Y., Strauss, J.R., Keohane, C.A., Doss, G.A., Chiu, S.H., Baillie, T.A., 2002. Metabolism of a thiazole benzenesulfonamide derivative, a potent and elective agonist of the human beta3-adrenergic receptor, in rats: identification of a novel isethionic acid conjugate. Drug Metab. Dispos. 30, 778-787. (Pubitemid 34671090)
76. Tanigawara, Y., Okamura, N., Hirai, M., Yasuhara, M., Ueda, K., Kioka, N., Komano, T., Hori, R., 1992. Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). J. Pharmacol. Exp. Ther. 263, 840-845.
77. Taub, M.E., Podila, L., Ely, D., Almeida, I., 2005. Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity. Drug Metab. Dispos. 33, 1679-1687. (Pubitemid 41539967)
78. Telbisz, A., Muller, M., Ozvegy-Laczka, C., Homolya, L., Szente, L., Varadi, A., Sarkadi, B., 2007. Membrane cholesterol selectively modulates the activity of the human ABCG2 multidrug transporter. Biochim. Biophys. Acta 1768, 2698-2713. (Pubitemid 350081032)
79. Troutman, M.D., Thakker, D.R., 2003. Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm. Res. 20, 1210-1224. (Pubitemid 36951846)
80. Uchiumi, T., Kohno, K., Tanimura, H., Hidaka, K., Asakuno, K., Abe, H., Uchida, Y., Kuwano, M., 1993a. Involvement of protein kinase in environmental stressinduced activation of human multidrug resistance 1 (MDR1) gene promoter. FEBS Lett. 326, 11-16. (Pubitemid 23200236)
81. Uchiumi, T., Kohno, K., Tanimura, H., Matsuo, K., Sato, S., Uchida, Y., Kuwano, M., 1993b. Enhanced expression of the human multidrug resistance 1 gene in response to UV light irradiation. Cell Growth Differ. 4, 147-157.
82. van Montfoort, J.E., Hagenbuch, B., Fattinger, K.E., Muller, M., Groothuis, G.M., Meijer, D.K., Meier, P.J., 1999. Polyspecific organic anion transporting polypeptides mediate hepatic uptake of amphipathic type II organic cations. J. Pharmacol. Exp. Ther. 291, 147-152. (Pubitemid 29451584)
83. Venkatakrishnan, K., von Moltke, L.L., Greenblatt, D.J., 2001. Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J. Pharmacol. Exp. Ther. 297, 326-337. (Pubitemid 32242593)
84. von Richter, O., Glavinas, H., Krajcsi, P., Liehner, S., Siewert, B., Zech, K., 2009. A novel screening strategy to identify ABCB1 substrates and inhibitors. Naunyn Schmiedebergs Arch. Pharmacol. 379, 11-26.
85. Wang, E., Casciano, C.N., Clement, R.P., Johnson, W.W., 2001a. The farnesyl protein transferase inhibitor SCH66336 is a potent inhibitor of MDR1 product Pglycoprotein. Cancer Res. 61, 7525-7529. (Pubitemid 32995043)
86. Wang, E.J., Casciano, C.N., Clement, R.P., Johnson, W.W., 2001b. Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem. Biophys. Res. Commun. 289, 580-585. (Pubitemid 33141095)
87. Yamada, A., Maeda, K., Kamiyama, E., Sugiyama, D., Kondo, T., Shiroyanagi, Y., Nakazawa, H., Okano, T., Adachi, M., Schuetz, J.D., Adachi, Y., Hu, Z., Kusuhara, H., Sugiyama, Y., 2007. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor. Drug Metab. Dispos. 35, 2166-2176. (Pubitemid 350146202)
88. Zhang, L., Zhang, Y.D., Strong, J.M., Reynolds, K.S., Huang, S.M., 2008. A regulatory viewpoint on transporter-based drug interactions. Xenobiotica 38, 709-724.
89. Zhou, S.F., 2008. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica 38, 802-832.